|
**Overview**: Infertility Screening Female Panel**Introduction**: The Infertility Screening Female Panel is a diagnostic tool designed to screen for female infertility using serum samples. In India, female infertility factors (anovulation, PCOS, diminished reserve) contribute to ~40-50 percent of cases, with early hormonal screening crucial for timely intervention. High morbidity from under-screening in rural/low-SES women, limited labs, delayed clomiphene/ART leading to prolonged infertility or emotional distress. Per endocrinology practices aligned with ICMR, FOGSI, and Indian Society for Assisted Reproduction guidelines, the test employs immunoassay for FSH, LH, prolactin, estradiol, and AMH over 1-2 days with high accuracy, valuable for assessing ovulatory function and ovarian reserve. This diagnostic falls under reproductive screening and targets women with infertility >1 year or irregular cycles, addressing accurate detection to guide ovulation induction or IVF. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise hormonal evaluation and improving fertility outcomes. Its serum-based approach ensures reliable multi-parameter assessment.**Other Names**: Infert Scr F Pnl.**FDA Status**: FDA approved, CLIA certified for endocrinology/immunology, compliant with 2025 standards.**Historical Milestone**: Female infertility screen standard; in India, used in fertility clinics.**Purpose**: The test assesses 5 parameters including FSH to guide female infertility screening, detect anovulation/reserve issues, inform therapy.**Test Parameters**: 1. FSH, 2. LH, 3. Prolactin, 4. Estradiol, 5. AMH.**Pretest Condition**: Fasting 10-12 hours recommended (day 2-5 of cycle); patients should report infertility.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on cycle regularity, prior pregnancies.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated infertility including prolonged childlessness, benefits of screening, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or incorrect cycle day can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Abnormal FSH/AMH indicate reserve issues; high prolactin suggests treatable cause, necessitating specialist input.**Specialist Consultation**: Reproductive endocrinologists should be consulted for management.**Additional Supporting Tests**: Pelvic ultrasound, semen analysis for confirmation.**Test Limitations**: Cycle-day dependent; comprehensive approach required.**References**: Indian Journal of Obstetrics and Gynaecology 2024, Infertility Studies India 2023. |
